Current Edition

Overcoming Regulatory Challenges in Cognitive Drug Development

In recent years, numerous pharmaceutical and biotechnology companies have undertaken development programmes intended to assess the efficacy of various pro-cognitive drugs on a wide variety of cognitive domains across several psychiatric and neurologic conditions. Henry J. Riordan, PhD, Executive Vice President of Medical and Scientific Affairs and Global Lead for Neuroscience at Worldwide Clinical Trials, presents an editorial on cognitive drug development by paying attention to overcoming regulatory challenges.